Matthew R. Patterson

Matt Patterson is a biotechnology executive with more than 30 years of experience in the research, development, and commercialization of innovative therapeutics. Matt most recently served as Chairman and CEO of Iris Medicine, Inc. from January 2022 until April 2024. In 2012 Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors at Audentes and formerly served as President until May 2018. Previously Matt worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is Chairman of the Board of Directors at Remix Therapeutics, Inc. He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020. Matt received his bachelor’s degree in biochemistry from Bowdoin College.